Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Research & Development (2016 - 2025)

Northwest Biotherapeutics' Research & Development history spans 16 years, with the latest figure at $5.6 million for Q4 2025.

  • Quarterly results put Research & Development at $5.6 million for Q4 2025, down 47.22% from a year ago — trailing twelve months through Dec 2025 was $28.8 million (down 17.49% YoY), and the annual figure for FY2025 was $28.8 million, down 17.49%.
  • Research & Development for Q4 2025 was $5.6 million at Northwest Biotherapeutics, down from $7.4 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $13.6 million in Q2 2022 to a low of $3.7 million in Q3 2021.
  • The 5-year median for Research & Development is $7.4 million (2025), against an average of $7.4 million.
  • The sharpest move saw Research & Development tumbled 78.78% in 2021, then surged 150.32% in 2022.
  • Year by year, Research & Development stood at $4.2 million in 2021, then skyrocketed by 123.41% to $9.4 million in 2022, then decreased by 20.3% to $7.5 million in 2023, then surged by 41.17% to $10.5 million in 2024, then tumbled by 47.22% to $5.6 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $5.6 million, $7.4 million, and $7.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.